We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

64 hedge funds and large institutions have $67.4M invested in Matinas BioPharma in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 7

306% more capital invested

Capital invested by funds: $16.6M → $67.4M (+$50.8M)

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

73% more funds holding

Funds holding: 37 → 64 (+27)

0.04% more ownership

Funds ownership: 0.32% → 0.37% (+0.04%)

Holders
64
Holders Change
+27
Holders Change %
+72.97%
% of All Funds
1.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
34
Increased
11
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.61M
2
BBA
Baker Bros. Advisors
New York
+$750K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$678K
4
ECM
ExodusPoint Capital Management
New York
+$549K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$356K

Top Sellers

Rank Fund Capital Flow
1
GPCM
Granite Point Capital Management
Massachusetts
-$946K
2
Millennium Management
Millennium Management
New York
-$341K
3
Victory Capital Management
Victory Capital Management
Texas
-$337K
4
TI
Telemetry Investments
New York
-$272K
5
LTFS
Ladenburg Thalmann Financial Services
Florida
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Boxer Capital
California
$23.1M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$12.1M +$147K +2,538 +2%
BBA
3
Baker Bros. Advisors
New York
$5.97M +$750K +12,948 +33%
BlackRock
4
BlackRock
New York
$4.65M +$1.61M +27,852 +212%
Victory Capital Management
5
Victory Capital Management
Texas
$3.11M -$337K -5,816 -18%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$1.97M +$74.3K +1,282 +8%
RJFSA
7
Raymond James Financial Services Advisors
Florida
$1.8M +$59.1K +1,020 +7%
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$1.78M +$3.48K +60 +0.4%
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$1.33M +$678K +11,706 New
SCA
10
STALEY CAPITAL ADVISERS
Pennsylvania
$1.14M +$116K +2,000 +25%
ECM
11
ExodusPoint Capital Management
New York
$1.07M +$549K +9,469 New
Wells Fargo
12
Wells Fargo
California
$843K +$174K +3,003 +68%
BCM
13
Bridgeway Capital Management
Texas
$772K – – –
Bank of Montreal
14
Bank of Montreal
Ontario, Canada
$697K +$356K +6,137 New
Renaissance Technologies
15
Renaissance Technologies
New York
$676K +$345K +5,959 New
DA
16
DCF Advisers
Connecticut
$622K +$318K +5,480 New
SG Americas Securities
17
SG Americas Securities
New York
$569K +$291K +5,015 New
Northern Trust
18
Northern Trust
Illinois
$542K +$1.85K +32 +0.7%
CIBC Private Wealth Group
19
CIBC Private Wealth Group
Georgia
$454K +$232K +4,000 New
WG
20
Winton Group
United Kingdom
$375K -$9.73K -168 -5%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$351K – – –
VF
22
Virtu Financial
New York
$333K +$170K +2,935 New
CAG
23
Crestwood Advisors Group
Massachusetts
$323K +$165K +2,850 New
OAM
24
Oxford Asset Management
United Kingdom
$251K +$110K +1,904 +614%
PTP
25
Platform Technology Partners
New York
$227K +$116K +2,000 New
1
2 3

MTNB Hedge Fund Activity: Q4 2019 in Review

64 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2019, worth a combined $67.4M — up 306% from $16.6M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new MTNB positions and 7 closed out — a net gain of 27 holders — while 11 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $1.61M. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $946K sold.

  • 64 institutional investors held Matinas BioPharma (MTNB) as of Q4 2019, up from 37 in Q3 2019.
  • Funds reported $67.4M of Matinas BioPharma stock for Q4 2019, up 306% quarter-over-quarter.
  • 34 funds opened new Matinas BioPharma positions in Q4 2019 and 7 closed out, a net change of +27 holders.
  • The largest Matinas BioPharma buyer in Q4 2019 was BlackRock, an estimated $1.61M added.
  • The largest Matinas BioPharma seller in Q4 2019 was Granite Point Capital Management, an estimated $946K sold.

Based on aggregated 13F filings for Q4 2019.